An experimental “corrector” drug from Centessa Pharmaceuticals normalized the levels of a target protein in two patients with an inherited disease that causes serious damage to the liver and lungs.
But one of the patients experienced serious liver toxicity that, while transient, was concerning enough to make Centessa open the study prematurely and reconsider the way its drug will be dosed for future patients, the company said in a news release.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
